CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study

G. Li, I. Sokal, Joseph Quinn, J. B. Leverenz, M. Brodey, G. D. Schellenberg, Jeffrey Kaye, M. A. Raskind, J. Zhang, E. R. Peskind, T. J. Montine

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Aβ42 as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD. METHODS: We determined the ratio of CSF tau/Aβ42 (T/Aβ) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12). RESULTS: We identified 16% of the control group with abnormally elevated CSF T/Aβ; all were 53 years or older. Using age-matched controls with normal CSF T/Aβ we showed that the high CSF T/Aβ subgroup of controls had significantly increased frequency of the ε4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture. CONCLUSIONS: These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.

Original languageEnglish (US)
Pages (from-to)631-639
Number of pages9
JournalNeurology
Volume69
Issue number7
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Alzheimer Disease
Odds Ratio
Dementia
Biomarkers
Prodromal Symptoms
Apolipoprotein E4
Spinal Puncture
Gene Frequency
Neurodegenerative Diseases
Cognitive Dysfunction
Research Personnel
Clinical Trials
Control Groups
Population
Genes
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Li, G., Sokal, I., Quinn, J., Leverenz, J. B., Brodey, M., Schellenberg, G. D., ... Montine, T. J. (2007). CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology, 69(7), 631-639. https://doi.org/10.1212/01.wnl.0000267428.62582.aa

CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment : A follow-up study. / Li, G.; Sokal, I.; Quinn, Joseph; Leverenz, J. B.; Brodey, M.; Schellenberg, G. D.; Kaye, Jeffrey; Raskind, M. A.; Zhang, J.; Peskind, E. R.; Montine, T. J.

In: Neurology, Vol. 69, No. 7, 08.2007, p. 631-639.

Research output: Contribution to journalArticle

Li, G, Sokal, I, Quinn, J, Leverenz, JB, Brodey, M, Schellenberg, GD, Kaye, J, Raskind, MA, Zhang, J, Peskind, ER & Montine, TJ 2007, 'CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study', Neurology, vol. 69, no. 7, pp. 631-639. https://doi.org/10.1212/01.wnl.0000267428.62582.aa
Li, G. ; Sokal, I. ; Quinn, Joseph ; Leverenz, J. B. ; Brodey, M. ; Schellenberg, G. D. ; Kaye, Jeffrey ; Raskind, M. A. ; Zhang, J. ; Peskind, E. R. ; Montine, T. J. / CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment : A follow-up study. In: Neurology. 2007 ; Vol. 69, No. 7. pp. 631-639.
@article{a5557546ef2e430da3ca3183292fbff0,
title = "CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study",
abstract = "BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Aβ42 as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD. METHODS: We determined the ratio of CSF tau/Aβ42 (T/Aβ) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12). RESULTS: We identified 16{\%} of the control group with abnormally elevated CSF T/Aβ; all were 53 years or older. Using age-matched controls with normal CSF T/Aβ we showed that the high CSF T/Aβ subgroup of controls had significantly increased frequency of the ε4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture. CONCLUSIONS: These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.",
author = "G. Li and I. Sokal and Joseph Quinn and Leverenz, {J. B.} and M. Brodey and Schellenberg, {G. D.} and Jeffrey Kaye and Raskind, {M. A.} and J. Zhang and Peskind, {E. R.} and Montine, {T. J.}",
year = "2007",
month = "8",
doi = "10.1212/01.wnl.0000267428.62582.aa",
language = "English (US)",
volume = "69",
pages = "631--639",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment

T2 - A follow-up study

AU - Li, G.

AU - Sokal, I.

AU - Quinn, Joseph

AU - Leverenz, J. B.

AU - Brodey, M.

AU - Schellenberg, G. D.

AU - Kaye, Jeffrey

AU - Raskind, M. A.

AU - Zhang, J.

AU - Peskind, E. R.

AU - Montine, T. J.

PY - 2007/8

Y1 - 2007/8

N2 - BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Aβ42 as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD. METHODS: We determined the ratio of CSF tau/Aβ42 (T/Aβ) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12). RESULTS: We identified 16% of the control group with abnormally elevated CSF T/Aβ; all were 53 years or older. Using age-matched controls with normal CSF T/Aβ we showed that the high CSF T/Aβ subgroup of controls had significantly increased frequency of the ε4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture. CONCLUSIONS: These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.

AB - BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Aβ42 as biomarkers of the dementia or prodromal stages of AD, we are unaware of any study to evaluate these potential CSF biomarkers of latent AD. METHODS: We determined the ratio of CSF tau/Aβ42 (T/Aβ) using Luminex reagents in 129 control individuals that spanned from 21 to 100 years of age; for comparison we included patients with MCI (n = 12), probable AD (n = 21), or other neurodegenerative diseases (n = 12). RESULTS: We identified 16% of the control group with abnormally elevated CSF T/Aβ; all were 53 years or older. Using age-matched controls with normal CSF T/Aβ we showed that the high CSF T/Aβ subgroup of controls had significantly increased frequency of the ε4 allele of the apolipoprotein E gene and significantly increased risk of conversion to MCI during follow-up of up to 42 months suggesting that they had latent AD at the time of lumbar puncture. CONCLUSIONS: These generally applicable methods establish cutoff values to identify control individuals at increased risk of conversion to mild cognitive impairment which may be useful to people weighing the risk-benefit ratio of new preventive therapeutics and to researchers striving to enrich clinical trial populations with people with latent Alzheimer disease.

UR - http://www.scopus.com/inward/record.url?scp=34547890294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547890294&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000267428.62582.aa

DO - 10.1212/01.wnl.0000267428.62582.aa

M3 - Article

C2 - 17698783

AN - SCOPUS:34547890294

VL - 69

SP - 631

EP - 639

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -